Medusa Exenatide XL: Interim Phase Ia data

Flamel said interim data from a 2-part Phase Ia trial in healthy volunteers showed that single ascending doses of FT228 met all safety and pharmacokinetic endpoints. In part 1, 40 subjects received FT...